Quoin Pharmaceuticals Ltd (QNRX) Stock Analysis

Q: Is QNRX stock a good investment?

The cached TradeMates AI model rates Quoin Pharmaceuticals Ltd as AVOID with an investment score of 28/100. The AI model recommends an AVOID rating on Quoin Pharmaceuticals (QNRX). The company is pre-revenue with severe cash burn (-$13.54M in 2025) and under 4 months of cash runway, making equity dilution imminent. This is algorithmic model output, not personal investment advice.

Q: Is QNRX stock a buy?

The TradeMates model verdict for QNRX is AVOID with an investment score of 28/100. Treat this as a model signal to review, not a personal buy recommendation.

Verdict: AVOID

Pre-revenue orphan drug pipeline faces critical cash exhaustion within 4 months, making severe equity dilution the dominant risk over clinical timing.

Investment score: 28/100

Analysis as of 2026-08-28

Is Quoin Pharmaceuticals Ltd stock worth reviewing? AI model thesis

The AI model recommends an AVOID rating on Quoin Pharmaceuticals (QNRX). The company is pre-revenue with severe cash burn (-$13.54M in 2025) and under 4 months of cash runway, making equity dilution imminent.

7-factor investment score

Valuation: 15/100 (weight 20%)
Financial Health: 10/100 (weight 15%)
Technical Momentum: 40/100 (weight 15%)
Earnings Quality: 25/100 (weight 15%)
Insider Sentiment: 50/100 (weight 10%)
Analyst Consensus: 60/100 (weight 10%)
Risk-Adjusted Return: 20/100 (weight 15%)

Quoin Pharmaceuticals Ltd opportunities and risks

What speaks for QNRX

Phase 3 Clinical Progress for QRX003

What speaks against QNRX

Imminent Cash Runway Exhaustion (<4 Months)

Peers and competitors

Trailing-twelve-month ratios
Ticker	P/E	P/S	EV/EBITDA	Gross margin	Net margin	FCF yield
QNRX	n/a	0.0x	n/a	0.0%	0.0%	-116.5%
CMMB	n/a	0.0x	n/a	0.0%	0.0%	-66.8%
NRSN	n/a	0.0x	n/a	0.0%	0.0%	-24.2%
PLUR	n/a	15.3x	n/a	19.0%	-2424.7%	-131.0%
Peer median	n/a	0.0x	n/a	0.0%	0.0%	-66.8%

Frequently asked questions about Quoin Pharmaceuticals Ltd (QNRX)

Is QNRX stock a good investment?

The cached TradeMates AI model rates Quoin Pharmaceuticals Ltd as AVOID with an investment score of 28/100. The AI model recommends an AVOID rating on Quoin Pharmaceuticals (QNRX). The company is pre-revenue with severe cash burn (-$13.54M in 2025) and under 4 months of cash runway, making equity dilution imminent. This is algorithmic model output, not personal investment advice.

Is QNRX stock a buy?

The TradeMates model verdict for QNRX is AVOID with an investment score of 28/100. Treat this as a model signal to review, not a personal buy recommendation.